{"name":"GemVax & Kael","slug":"gemvax-kael","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOQmhONnR0TFVQMEVNR1FaR0o2R1ZGdDkxLWdobVVNX05tZ21BVGFiQlN4NTd5LXJKSnNfTmZhZEFzMjNieThveWNXNWVCZWpzenZxY2VYeGg5ZlZzOVhGaElMRmJ6aVNMUkZvUnFyaENraF9CcGJLM29lM1BoQV81SdIBlAFBVV95cUxPclJtZk1MaDlMb3BaS0ptV3hRdWs3Wkxhb3pJZkpyaVJ1T3hUQlNmVEJuUEZ5Z1d4bGhVd2RPQm5zamtXc3BOLVI1VjF5bTBodFZVM0VqUmYtUHIzelh1UlNIcWNvZ0J0RERpenc5OGh2ZDNLR0lVTDAzVVNxVFoxSlBkSVFlNVhIcHYwZUFCUFNydDVh?oc=5","date":"2025-12-08","type":"pipeline","source":"Chosunbiz","summary":"Samsung Pharm secures rights to PSP drug and sees shares surge - CHOSUNBIZ - Chosunbiz","headline":"Samsung Pharm secures rights to PSP drug and sees shares surge - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTFBNV3dYZU03dVBDeDFpTnBZR1pUZmtrcFNVRl80aFgteW5LdWRlcG54MmRLckpFaU55eXY3VlFsUEpQTW0yWWdVblo0YWJOZFk?oc=5","date":"2025-12-05","type":"pipeline","source":"매일경제","summary":"GemVax & KAEL announced on the 5th that it has signed a technology transfer agreement with Samsu.. - 매일경제","headline":"GemVax & KAEL announced on the 5th that it has signed a technology transfer agreement with Samsu.. - 매일경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQSGJvdXJxZzhmaVpISEV3ZGFqSnRMZDlYYnRxM1A5VDItZXJjVFpDcXNrYU9zN1FoUl9IX0VDWjdTYlh2LWRLRWJDaWhTbVFvNG5MQjdfZTJMSFMwQ2tkUTlXREN3YjZSY2U3ZGRXLXIzQUwzc29WTWhad3M3YUtxRdIBlAFBVV95cUxOSU5NZmJKX2N6RXN1YmtEdlNMQldHSnExMGs3MjZJU1Fmc0dhbno1RUlnZGpzUGh3OVkxYWRwbUQ5ZHdzWnhwcTJ2T0dFRk5Nbk5PQ2YzMUN0SXdZTEVWM0xVQ1hCVGx6V0lkaGJ5aUxRcTlhZGlqUFlYN3NWU0NxdWlYR3lXc1AyRHZRVm5kYUlLcXQy?oc=5","date":"2025-11-12","type":"trial","source":"Chosunbiz","summary":"GemVax & KAEL faces funding crunch after rights offering canceled and trial fails - CHOSUNBIZ - Chosunbiz","headline":"GemVax & KAEL faces funding crunch after rights offering canceled and trial fails - CHOSUNBIZ","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQRzY2TXA2X29UeTBPYXhnTkRhUV9YNVF1dURMRlFxX25KaUxqVlNNcjZBclZUU2x4SEw5eVZsQUlWeEY0SHBjc29pUWh3eEMyZDVONlRldUR5RGFxdWhDWjEyZk05MXBRUlFieVZUM2ZFY0ctaDF6YUxXeE5RUDRuR9IBlAFBVV95cUxQa0ZWaEV4VjBveDlDNlpDOXhOLVlUVmRfaFNpRTAycEJiNlI3YjhVdElRdkdDeDlITE4xeGFkN010RlpCUlBUMmdLWDBrcm5RNDZhYjdoYWZzUnl3clBLSXN3M1A5Y05fX05FYUdQWGRkQU1teWhxVDZaZER3YktoMGZaZFNKYjJSYjBvZkdDUmJHMkQ5?oc=5","date":"2025-09-01","type":"pipeline","source":"Chosunbiz","summary":"GemVax & KAEL faces equity dilution concerns amid 250 billion won capital increase - CHOSUNBIZ - Chosunbiz","headline":"GemVax & KAEL faces equity dilution concerns amid 250 billion won capital increase - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQdW5UMHVnV0lOTmVlWVN1V2M0cENmMm1jSnllOTd6TGJqUGtLQ1k5OVpXbF9mLUlzU2pydVBrcGRqSDFvZ3BqLTRaVGNjNGtvYi1rSG1idEN6eHIxakdPSEcxNU54V2kxMVJjeHYyZnVBejNxc1BZamx6OHJkTll4SFB5cG9MZzVUNXpOOV91bWVaVjBWUnlOV09yLW5hN2MyWlc2eW11SnJiZHduV3J4eUJia1ZUanhJcGhSdTBUYw?oc=5","date":"2024-10-29","type":"trial","source":"Fierce Biotech","summary":"Korea's GemVax misses mark with peptide drug in phase 2a study in progressive supranuclear palsy - Fierce Biotech","headline":"Korea's GemVax misses mark with peptide drug in phase 2a study in progressive supranuclear palsy","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9jSVNfamF6UVMzZU52TnZzRG50NE9pTEhWSEJfYzZWWUNXTjI5NlBVUkl1WFFLTjFQNWpIaWdVYWlxbHhJX2JQQUJUeXZOdHZNWmdWWXZTckZZemVwdW9mZkRtQzBZN1M5SE9sRGpn0gFyQVVfeXFMUE1jOG9vRmt2UGQyLTA2YTdRSmp3Qm8wR2xQVTJpQlp4WVg1aENpekNqaFVNeVBoa0V3aXZPTWZ1WElLNm93NnN1eXVQcmZ5R21CTmRTUTN5S1k2dzEzS19JTERhWFFSLXZnTzlSbUdvQVhB?oc=5","date":"2024-10-25","type":"trial","source":"koreabiomed.com","summary":"GemVax & KAEL’s GV1001 fails to show effects in P2a trial of progressive supranuclear palsy - koreabiomed.com","headline":"GemVax & KAEL’s GV1001 fails to show effects in P2a trial of progressive supranuclear palsy","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1DMG5Uejh6UWVDTm12OHNPMGE0TjdTRE1kRWlEU2J3WUptTndvcTNITl8tVzQ2akRmdXZwYVZYTUdNb3lKdUllVXZlM2ZqM2xOcDQ1ci01ZEVkWDQxTjdpUHVVcVYwVWtrVkotTmVB0gFyQVVfeXFMUC0xSXdwLUJkMlZyd19NbjgxdkVsQmUzQjVfNXVEeHdYc3R3WHdaZVNEYUE1c3YwN082LVRTUGtsRkM4R0FIN3U2XzFRb3V1NHphblRqcWR6WXRPMlUyalQtRF9FMmN0RUVFYUYtSHNrMVBR?oc=5","date":"2024-03-07","type":"trial","source":"koreabiomed.com","summary":"Samsung Pharm OKed for simplified phase 3 Alzheimer's study of GV1001 - koreabiomed.com","headline":"Samsung Pharm OKed for simplified phase 3 Alzheimer's study of GV1001","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE91WUI4WkIxazVHV1p1ZmZ0ZW9iNHgxMHhqbXVPOUtGVFBueE1NT3ZUZUJvSU1FNHAwVG1UTkxVUW1TYTRQNW9ja3VEa3NwYVNhcnJFQjZHOUJGVXB3RUlNMWVFc29hc1lON2ZyTzhR0gFyQVVfeXFMT0ZvZjlGa1lBWWpVWW5waUZNWVNaT01kcGlyWmVWb0ExYU8tQm5fMlgzMU5aclpkaFpJS3diM3lOZXZ3QUNJUmx5Y0R3dDViNTlxblFYUGctQWNqS085dVR5LWw4SjM5MDJVWHFfYkpZR1lR?oc=5","date":"2023-12-19","type":"regulatory","source":"koreabiomed.com","summary":"Gemvax & Kael seeks FDA nod for phase 2 study of PSP treatment - koreabiomed.com","headline":"Gemvax & Kael seeks FDA nod for phase 2 study of PSP treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBIakl6M1lvN3RxZTd1a3FFQmFhMjVKZndVcDUzZ2pWMVlPR2E3eG9PNTVYa2d3Mm16eE5NaE96WDlmLW5zNkktVlQ1OGxEcXNYZUZxTVlkNmNmMzlDLUNPeDRSckJuTHNXWFZB0gFvQVVfeXFMT3FLak1vYW8yaUJUR1BTUTg1UmZIbXp4UnV6cWwwRHpMcVVmX1otcHllZ1NPVlU1ZXhLNHR2OU94bnZLNDZpU3cxV05LVVNBUEpCSk5KYlhhd0V0b045UmZwM3BZeTJqLUl1bDNUOTZB?oc=5","date":"2017-03-27","type":"deal","source":"koreabiomed.com","summary":"GemVax & KAEL partners with PAREXEL for Alzheimer tests - koreabiomed.com","headline":"GemVax & KAEL partners with PAREXEL for Alzheimer tests","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}